Division of GlaxoSmithKline PLC
Latest From GlycoVaxyn AG
A broad vaccines portfolio, a blockbuster asset swap with Novartis, and an R&D revamp including significant, long-term investment in technology platforms have cemented GlaxoSmithKline’s leadership in a perennially lucrative business that is core to its corporate ethos. Why hasn’t anyone seemed to notice?
A pair of technology platforms acquired in the 2010 buyout of Crucell is enabling J&J to produce higher yields of vaccines and deliver safely using adenovirus vectors.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February 2015.
Sanofi moves into ROR gamma T R&D for potential autoimmune therapies in collaboration with Lead Pharma, while Intrexon acquires Belgium’s ActoGeniX and its platform technology for creating a novel class of biotherapeutics targeting the oral and GI tracts. Teva heads off dispute with Eagle, bringing in new bendamustine formulation.
- Therapeutic Areas
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- GlaxoSmithKline PLC
- Senior Management
Philippe Dro, CEO
Michael Wacker, PhD, CSO
Veronica Gambillara, Head, Partnering
- Contact Info
Phone: (41) 44 733 85 85
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.